Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Conestoga Micro Cap Composite. This analysis is provided for institutional research purposes only and is not investment advice.
"Conestoga's Micro Cap strategy underperformed in Q3 as micro caps faced the greatest market headwinds. Health Care holdings struggled with bioprocessing industry challenges while Construction Partners benefited from infrastructure spending tailwinds."
Conestoga's Micro Cap Growth Composite declined 13.34% net of fees in Q3 2023, underperforming the Russell Micro Cap Growth Index's 11.95% decline. The challenging performance reflected broad-based weakness in micro cap stocks, where smaller market capitalization companies faced the greatest headwinds. Stock selection was particularly difficult in Health Care and Consumer Discretionary sectors, though Technology provided positive contributions. Health Care holdings faced industry-wide challenges including inventory destocking and elongated sales cycles affecting bioprocessing companies like BioLife Solutions and Repligen. The portfolio benefited from Construction Partners, which beat earnings estimates by 17% as it converted post-inflationary backlog, with demand remaining robust from the early stages of the 2021 Federal infrastructure bill. Technology holdings like PROS Holdings and Q2 Holdings reported better-than-expected results. Despite 2023 challenges, the strategy maintains its focus on higher-quality companies with positive earnings and lower debt levels, positioning for potential outperformance in a higher interest rate environment. The longer-term track record remains strong with outperformance in each of the first three years since inception.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The strategy demonstrates solid conviction through detailed analysis of individual holdings with specific performance drivers and clear investment rationales. Named positions are discussed with substantive commentary and the manager maintains conviction in the quality-focused approach despite near-term challenges. However, the diversified micro cap approach with 25-40 holdings prevents this from reaching the highest conviction levels.
Growth Outlook
The manager expresses caution about higher interest rates staying elevated for longer and increased recession expectations for 2024. While acknowledging some positive catalysts like infrastructure spending, the overall market outlook is cautious given the challenging environment for micro cap stocks and broader economic uncertainties.
Risk Appetite
The portfolio maintains its existing positioning with selective activity - adding one new position (Definitive Healthcare) and selling one (Nanostring Technologies). The strategy continues to emphasize higher-quality companies but shows no clear directional bias toward increasing or decreasing risk appetite.
Capital Deployment
Limited net deployment activity with one new position added and one sold, representing capital rotation rather than significant net deployment. The modest cash position (averaging 3%) and selective trading activity suggests neutral deployment stance with slight positive bias from the new addition.
Forward Guidance
The manager shows slight caution in forward deployment, focusing on maintaining quality standards rather than aggressive deployment. While not explicitly defensive, there's no indication of accelerated capital deployment or aggressive positioning changes planned.
Language Signal
Language contains more risk-oriented terms including 'challenging,' 'headwinds,' 'difficult,' and 'underperformance' while positive language around specific holdings and longer-term prospects provides some balance. The net directional language tilts slightly negative.
Perceived Risk
The manager identifies multiple specific risks including higher interest rates, recession potential for 2024, and industry-specific challenges in bioprocessing. The discussion of micro cap underperformance and challenging market conditions for smaller companies demonstrates meaningful risk awareness without reaching extreme levels.
Opportunity Density
The manager sees selective opportunities as evidenced by the addition of Definitive Healthcare, but the overall tone suggests a more challenging environment for micro cap investing. The emphasis on maintaining quality standards and the performance challenges described indicate a more selective opportunity set.
Time Horizon
The strategy demonstrates a multi-year investment horizon with references to longer-term prospects remaining bright despite near-term challenges. The manager's willingness to hold through current difficulties and focus on fundamental quality over short-term performance indicates a patient, longer-term approach typical of micro cap investing.
